Eiger BioPharmaceuticals to Participate in Upcoming August 2021 Investor Conferences
|
PALO ALTO, Calif., Aug. 3, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory, President and CEO, will participate in two investor conference events in August:
Eiger will also host one-on-meetings with investors at both conferences. A live webcast of the Wedbush PacGrow panel discussion will be available on the Eiger Biopharmaceuticals website at www.eigerbio.com in the Investors section. A replay of the webcast will be available approximately one hour following the live event. About Eiger Eiger's lead clinical programs are focused on the development of foundational therapies for Hepatitis Delta Virus (HDV) infection, the most serious form of viral hepatitis, with two complementary HDV treatments. Lonafarnib is a first-in-class, oral prenylation inhibitor in a global Phase 3 trial. Peginterferon Lambda is a first-in-class, type III, well-tolerated interferon entering Phase 3. Zokinvy® for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient progeroid laminopathies is the Company's first FDA approved product. A Marketing Authorization Application (MAA) is under review by the European Medicines Agency (EMA). For additional information about Eiger and its clinical programs, please visit www.eigerbio.com. Investors and Media: Charles Butler – VP, Investor Relations and Corporate Communications
SOURCE Eiger BioPharmaceuticals, Inc. |
||
Company Codes: NASDAQ-NMS:EIGR |
View original content to download multimedia: